CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

203155Orig1s000

MICROBIOLOGY REVIEW(S)
Product Quality Microbiology Review
Positron Emission Tomography (PET) Products

06 September 2012

NDA: 203-155/N-000

Drug Product Name
Proprietary: none
Non-proprietary: Choline C-11 Injection

Review Number: 2

Dates of Submission(s) Covered by this Review

<table>
<thead>
<tr>
<th>Submit Date</th>
<th>Received Date</th>
<th>Review Request Date</th>
<th>Assigned to Reviewer Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>06 September 2012</td>
<td>06 September 2012</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

Submission History (for amendments only)

<table>
<thead>
<tr>
<th>Submit Date(s)</th>
<th>Microbiology Review #</th>
<th>Review Date(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 December 2011</td>
<td>1</td>
<td>14 August 2012</td>
</tr>
</tbody>
</table>

Applicant/Sponsor
Name: Mayo Clinic PET Radiochemistry Facility (MCPRF)
Address: Mayo Clinic
200 First Street SW
Rochester, MN 55905-0001
Representative: Joseph C. Hung, PhD, BCNP
Director of MCPRF
Telephone: 507-284-4104

Name of Reviewer: Robert J. Mello, Ph.D.

Conclusion: The application is recommended for approval from a microbiology product quality standpoint.
Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: New Drug Application 505(b)(2)

2. SUBMISSION PROVIDES FOR: Marketing Authorization

3. MANUFACTURING SITE: Mayo Clinic PET Radiochemistry Facility (MCPRF)
   Mayo Clinic
   200 First Street SW
   Rochester, MN 55905-0001

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY: Injection; intravenous; 4-33.1mCi/mL @ end of synthesis (EOS). The bulk drug is collected into type I molded glass vials sealed with stoppers.

5. METHOD(S) OF STERILIZATION: Sterile station.

6. PHARMACOLOGICAL CATEGORY: Positron Emission Tomography (PET) Radiodiagnostic Imaging Agent

B. SUPPORTING/RELATED DOCUMENTS:

C. REMARKS:
   - The NDA amendment was submitted in eCTD format.
   - On 16 August 2012 a microbiology information request was transmitted to the applicant concerning deficiencies in environmental monitoring and media fill support of . The applicant responded on 24 August 2012 but the information provided did not fully address the original deficiencies. A T-con between the applicant and the Division (including this reviewer) was held on 31 August 2012 to clarify the requirements to satisfy the deficiencies in the applicant's media fill program.
   - The applicant submitted an additional amendment concerning the media fills on 06 September 2012.

Filename: N203155N000R2.doc
Executive Summary

I. Recommendations

A. Recommendation on Approvability - Recommend Approval

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable - N/A

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology - Sterile collection vials are assembled in an environment. The assembled collection vial is prepared with that penetrate the vial’s sterile seal. for sterility and bacterial endotoxins testing. The product vial and samples are placed in a protective device for storage and transfer.

B. Brief Description of Microbiology Deficiencies - None

C. Assessment of Risk Due to Microbiology Deficiencies - N/A

III. Administrative

A. Reviewer’s Signature: ________________________________
   Robert J. Mello, Ph.D.
   Senior Microbiology Reviewer

B. Endorsement Block: ________________________________
   David Hussong, Ph.D.
   Director, New Drug Microbiology Staff

3 Page(s) has been Withheld in Full as b4 (CCI/TI) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT J MELLO
09/07/2012

DAVID HUSSONG
09/07/2012

The reviewer has provided a recommendation for approval based on an evaluation of the applicant's risk assessment and corrected procedures. I concur that the microbiology procedures and controls are appropriate for approval.
Product Quality Microbiology Review
Positron Emission Tomography (PET) Products

14 August 2012

NDA: 203-155/N-000

Drug Product Name
Proprietary: none
Non-proprietary: Choline C-11 Injection

Review Number: 1

Dates of Submission(s) Covered by this Review

<table>
<thead>
<tr>
<th>Submit</th>
<th>Received</th>
<th>Review Request</th>
<th>Assigned to Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>08 February 2012</td>
<td>08 February 2012</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>13 February 2012</td>
<td>13 February 2012</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>05 June 2012</td>
<td>05 June 2012</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

Submission History (for amendments only): N/A

Applicant/Sponsor
Name: Mayo Clinic PET Radiochemistry Facility (MCPRF)
Address: Mayo Clinic
200 First Street SW
Rochester, MN 55905-0001
Representative: Joseph C. Hung, PhD, BCNP
Director of MCPRF
Telephone: 507-284-4104

Name of Reviewer: Robert J. Mello, Ph.D.

Conclusion: The application is recommended for approval pending the receipt of additional information.
Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: New Drug Application 505(b)(2)

2. SUBMISSION PROVIDES FOR: Marketing Authorization

3. MANUFACTURING SITE: Mayo Clinic PET Radiochemistry Facility (MCPRF)
   Mayo Clinic
   200 First Street SW
   Rochester, MN 55905-0001

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY: Injection; intravenous; 4-33.1mCi/mL @ end of synthesis (EOS). The bulk drug is collected into type I molded glass vials sealed with stops.

5. METHOD(S) OF STERILIZATION: Sterile

6. PHARMACOLOGICAL CATEGORY: Positron Emission Tomography (PET) Radiodiagnostic Imaging Agent

B. SUPPORTING/RELATED DOCUMENTS:
   • DMF
   • DMF
   • DMF

C. REMARKS:
   • The NDA was submitted in eCTD format.
   • The submission was initially granted Priority Review status with a PDUFA goal date of 12 June 2012.
   • An NDA Amendment dated 17 April 2012 was classified as a major amendment submitted within 3 months of the PDUFA goal date. Therefore, in a letter dated 10 May 2012, the Applicant was notified that the PDUFA goal date was being extended to 12 September 2012.
   • The 08 February 2012, 13 February 2012 and 05 June 2012 submissions were responses to both microbiology and chemistry information requests.

filename: N203155N000R1.doc
Executive Summary

I. Recommendations

A. Recommendation on Approvability - The application is recommended for approval pending the receipt of additional information.

B. Recommendations on Phase 4 Commitments and/or Agreements - N/A

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – Sterile collection vials are assembled in an [redacted] environment. The assembled collection vial is prepared with [redacted] for sterility and bacterial endotoxins testing. The product vial and samples are placed in a protective device [redacted] for storage and transfer.

B. Brief Description of Microbiology Deficiencies - The proposed [redacted] month frequencies for viable environmental monitoring cannot assure that the microbial integrity of the [redacted] manufacturing area is being maintained during routine manufacturing operations. Also, the media fill program is inadequate in that it does not simulate all production operations, it does not use microbial growth media in place of drug product and not all of the simulated product is incubated.

C. Assessment of Risk Due to Microbiology Deficiencies - N/A

III. Administrative

A. Reviewer's Signature: ____________________________

   Robert J. Mello, Ph.D.
   Senior Microbiology Reviewer

B. Endorsement Block: ____________________________

   David Hussong, Ph.D.
   Director, New Drug Microbiology Staff

12 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT J MELLO  
08/14/2012

DAVID HUSSONG  
08/14/2012

This review identifies two issues that the applicant should address prior to approval of the application.
# PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

**NDA Number:** 203-155  
**Applicant:** Mayo Clinic PET Radiochemistry Facility (MCPRF)  
**Submit Date:** 12/12/2011  
**Drug Name:** $[^{11}\text{C}]$ Choline Injection; 4-33.1 mCi/ml EOS  
**NDA Type:** 505(b)(2)  
**Received Date:** 12/12/2011

The following are necessary to initiate a review of the NDA application:

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?</td>
<td>X</td>
<td></td>
<td>Section 3.2.P.2.5, and Section 3.2.P.8</td>
</tr>
<tr>
<td>2 Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?</td>
<td>X</td>
<td></td>
<td>Section 3.2.P.3.3, and Sections 3.2.S.2.2,.3 and -.4</td>
</tr>
<tr>
<td>3 Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?</td>
<td>X</td>
<td></td>
<td>Insufficient information provided to validate procedures</td>
</tr>
<tr>
<td>4 Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?</td>
<td>X</td>
<td></td>
<td>Product is not preserved. Container closure integrity studies were not submitted.</td>
</tr>
<tr>
<td>6 Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?</td>
<td>X</td>
<td></td>
<td>Section 3.2.P.5.1</td>
</tr>
<tr>
<td>7 Has the applicant submitted the results of analytical method verification studies?</td>
<td>X</td>
<td></td>
<td>Section 3.2.P.5.3.2.5 (pages 9-10), but information is insufficient</td>
</tr>
<tr>
<td>8 Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?</td>
<td>-</td>
<td>-</td>
<td>Not applicable</td>
</tr>
<tr>
<td>9 Is this NDA fileable? If not, then describe why.</td>
<td>X</td>
<td></td>
<td>The submission is fileable but additional information is required to complete the review.</td>
</tr>
</tbody>
</table>

**Additional Comments:** The submission is fileable.  
In order to complete a substantive review of the submission, additional information will be requested from the applicant (see below). DMF was
referenced for the preparation and (b)(4) of the empty, (b)(4) sterile collection vials, and it will be reviewed as part of the submission.

Robert J. Mello, Ph.D.
Senior Review Microbiologist

David Hussong, Ph.D.
Director, OPS/NDMS

Product Quality Microbiology Assessment

The submission contains numerous references to documents and procedures but very little actual data on the microbial controls supporting the (b)(4) manufacturing process. To adequately assess the manufacturing process and the microbial quality of the finished drug product, the following information request should be conveyed to the applicant.

Please provide the following additional information:

[END]
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT J MELLO
01/10/2012

DAVID HUSSONG
01/10/2012